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Abstract (N=264 words) 
A genome-wide exome association study has identified the transmembrane 6 superfamily 
member 2 (TM6SF2) rs58542926 variant encoding an E167K substitution as a genetic 
determinant of hepatic steatosis in nonalcoholic fatty liver disease (NAFLD). The role of this 
variant across a spectrum of liver diseases and pathologies and on serum lipids comparing viral 
hepatitis to NAFLD, and viral load in chronic viral hepatitis, and its intrahepatic molecular 
signature, have not been well characterized. We undertook detailed analyses in 3,260 subjects 
with viral and non-viral liver diseases and in healthy controls. Serum inflammatory markers and 
hepatic expression of TM6SF2 and genes regulating lipid metabolism were assessed in a subset 
with chronic hepatitis C (CHC). The rs58542926 T allele was more prevalent in 502 NAFLD 
patients than controls (p=0.02), but not different in cohorts with CHC (n = 2,023) and CHB (n = 
507). The T allele was associated with alterations in serum lipids and hepatic steatosis in all 
diseases, and with reduced hepatic TM6SF2 and MTTP expression expression. Interestingly, the 
substitution was associated with reduced CHC viral load, but increased HBV-DNA. The 
rs58542926 T allele had no effect on inflammation, impacted on ≥F2 fibrosis in CHC and 
NAFLD assessed cross-sectionally (OR: 1.39 (95% CI = 1.04-1.87 and OR: 1.62, 95% CI: 1.03-
2.52, respectively, p<0.03 for both), but had no effect on fibrosis progression in 1174 patients 
with CHC and a known duration of infection. We conclude that the TM6SF2 E167K substitution 
promotes steatosis and lipid abnormalities in part by altering TM6SF2 and MTTP expression and 
differentially impacts CHC and CHB viral load, while effects on fibrosis are marginal.  
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 INTRODUCTION 
 Ectopic lipid accumulation associated with the increasing worldwide prevalence of 
obesity (
1
) is linked with tissue meta-inflammation (
2
), resulting in organ dysfunction, excess 
morbidity and mortality (
3
). In this context, hepatic rather than visceral fat deposition is more 
tightly linked with the metabolic complications of obesity (
4
) and it is therefore not surprising 
that steatosis is now the most commonly observed histological abnormality across a spectrum of 
liver diseases (
5
). The heritability of steatosis is therefore of considerable interest, with a 
landmark genome-wide association study (GWAS) (
6
) and subsequent reports (
7
) demonstrating 
unequivocal evidence that a non-synonymous single-nucleotide polymorphism (SNP) in patatin-
like phospholipase domain containing 3 (PNPLA3) rs738409 is associated not only with steatosis 
severity, but with the extent of fibrosis in NAFLD (
8
). More recently, in 7176 individuals of 
European ancestry, a GWAS meta-analysis in NAFLD using 2.4 million SNPs imputed to 
HapMap, identified additional common variants at 5 loci containing multiple genes 
(NCAN/TM6SF2/CILP2/PBX4) that impacts steatosis (
7
). A subsequent genome-wide exome 
association study with functional analysis (
9
) identified an rs58542926 C>T variant in the 
transmembrane 6 superfamily member 2 (TM6SF2) gene, which encodes an amino acidic 
substitution (E167K) as the causative variant for the GWAS signal. The impact of TM6SF2 
rs58542926 as a determinant of liver fat in NAFLD is well-established (
10,11,12
). While there is 
evidence suggesting a role for this variant in NAFLD-associated liver fibrosis, this finding is not 
unequivocal (
10,11,12,13,14
), and is debatable in the case of CHC (
15,16
). There is no data on the role 
of rs58542926 in chronic hepatitis B (CHB).  
 With regard to the metabolic consequences of harboring the rs58542926 T allele, an 
association with lower levels of serum total cholesterol, LDL-cholesterol (LDL-C) and 
triglycerides (TG), and protection from atherosclerosis and cardiovascular events in NAFLD 
6 
 
(
9,11,17
) has been reported. This cardiovascular risk mitigation is likely a consequence of data 
(from mouse models and cell lines), suggesting that TM6SF2 modulates hepatic lipoprotein 
export (
9,18
). However, corroborating human data is absent, but required, given the limitations of 
the cell lines used in published reports (
15
). VLDL secretion is nearly absent in Huh7 cells (
19
) 
and HepG2 cells secrete relatively dense, lipid poor apolipoprotein B (apoB)-containing 
particles, unlike the buoyant VLDL particles secreted in vivo (
20
). The impact of TM6SF2 
rs58542926 polymorphisms on serum lipoproteins in patients with viral hepatitis is unknown.  
 A third unexplored but plausible consequence of TM6SF2 action is influences on viral 
load in chronic viral hepatitis. Both chronic hepatitis C and B (CHC and CHB) are associated 
with abnormalities in lipid metabolism (
21,22,23
), lipids play important roles in various aspects of 
the life cycle of the viruses (
24,25
), and we have shown that a variable fraction of HCV in serum is 
associated with triglyceride-rich lipoproteins (TRLs) called lipoviral particles that exhibit 
increased infectivity (
26
). Thus, it could be hypothesized that gene variants that modulate hepatic 
lipid metabolism and TG export could impact on viral load. 
 Based on these considerations, the aims of the present study were to clarify the influence 
of the TM6SF2 rs58542926 variant on the metabolic and histological features of liver diseases, 
comparing viral hepatitis to NAFLD, to explore effects on viral load and thirdly to investigate 
the impact of carriage of the T allele on the expression of hepatic TM6SF2 and genes modulating 
liver lipid accumulation. 
7 
 
Methods 
Patient cohort 
 The study comprised 3,260 consecutive subjects from the International Liver Disease 
Genetics Consortium (ILDGC) database. Details of the cohort and inclusion criteria have been 
reported (
27
). Briefly, for those with CHC, patients who had a liver biopsy with scoring for 
fibrosis stage and disease activity before anti-viral treatment were included. Patients were 
excluded if they had evidence of other liver diseases by standard tests. In addition to the 2,023 
with CHC, the cohort comprised 507 patients with CHB, 502 with NAFLD and 228 healthy 
controls. Only one of the patients with CHC was included in a recent report on TM6SF2 (
15
). The 
healthy Caucasian European control group was enrolled from Westmead hospital, Sydney, and 
reported no history of chronic liver disease. Details of the selection criteria for control subjects 
are presented in supplementary methods. 
 Ethics approval was obtained from the Human Research Ethics Committees of the 
Sydney West Local Health District and the University of Sydney. All other sites had ethics 
approval from their respective ethics committees. Written informed consent for genetic testing 
was obtained from all participants.  
Clinical and laboratory assessment 
 A detailed description of the baseline data collected at the time of liver biopsy and 
methods to estimate the duration of infection is provided in supplementary methods. Data 
included demographic parameters, alcohol intake, and routine laboratory variables including 
metabolic parameters. 
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Genotyping 
 Genotyping for TM6SF2 rs58542926 and PNPLA3 rs738409 was contracted to the 
Australian Genome Research Facility (AGRF; QLD, Australia). Samples were genotyped using 
the Sequenom MassARRAY system and iPLEX Gold chemistry. Further genotyping for both 
SNPs (n=1150) was undertaken using the TaqMan SNP genotyping allelic discrimination 
method (Applied Biosystems, Foster City, CA, USA). All genotyping was blinded to clinical 
variables. 
Liver Histopathology 
 Liver histopathology was scored according to METAVIR (
28
). Fibrosis was staged from 
F0 (no fibrosis) to F4 (cirrhosis). Necroinflammation (A) was graded as A0 (absent), A1 (mild), 
A2 (moderate), or A3 (severe). For NAFLD, the Kleiner classification was used (
29
).According 
to the classification of Bedossa et al., (
30
) histological features of steatohepatitis in CHC was also 
assessed in a subset of 112 patients infected with genotype 1. The inter-observer agreement 
between pathologists was studied previously and was good (κ = 77.5) for METAVIR staging 
using κ statistics (31).  Histopathology methods are detailed in the supplementary methods.  
Determination of inflammatory markers and mRNA levels of genes regulating lipid 
metabolism  
 Ninety well characterized patients with CHC underwent liver biopsy at Westmead 
Hospital, their details have been described previously (
32
). We assessed the relationship between 
rs58542926 genotype and the expression of TM6SF2, acyl-coenzyme A oxidase 1 (ACOX1) and 
microsomal triglyceride transfer protein (MTTP). The expression of sterol regulatory element 
binding protein-1c (SREBP-1c) and fatty acid synthase (FAS) was measured previously (
32
). The 
detailed methods have been described previously (
32
) and summarized in the supplementary 
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methods. Serum TNF-α, soluble tumor necrosis factor receptor 2 (sTNFR2) and IL-6 in these 
patients were measured by sandwich enzyme-linked immunosorbent assay (ELISA).  
 
Statistical Analysis 
 Statistical methods are detailed in the supplementary methods. All tests were two-tailed 
and p values <0.05 were considered significant. 
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Results 
Patient characteristics 
 The study comprised 3,260 consecutive subjects including 2,023 with CHC, 507 with 
CHB, 502 with NAFLD and 228 healthy controls. The clinical, anthropometric, biochemical and 
metabolic characteristic of the patients in the CHC cohort are presented in supplementary table 
1. The genotype distribution of TM6SF2 rs58542926 and PNPLA3 rs738409 was in Hardy-
Weinberg equilibrium supplementary table 2.   
Association between the TM6SF2 variant and viral, clinical and metabolic characteristics 
in CHC 
 The minor allele frequency (MAF) of TM6SF2 rs58542926 was 0.06, similar to that of 
the 228 Caucasian self-reported ‘healthy’ controls (MAF 0.07) (p=0.7 for trend) supplementary 
table 1. There was no significant difference in the rs58542926 genotype distribution according 
to patient country of origin (Australia, UK, Germany and Italy) (p=0.1 for trend).  
 Patients with the TM6SF2 rs58542926 TT genotype had significantly lower HCV viral 
load compared to subjects with CT or CC (p=0.007), after Bonferroni correction for multiple 
comparisons (Table 1). In another analysis, mean HCV viral load was lower in subjects with 
CT/TT compared to those with CC (5.74±0.73 vs. 5.59±0.0.76; p=0.02). To adjust for the effect 
of confounding factors, TM6SF2 rs58542926 TT genotype still associated inversely with HCV-
RNA levels in a multivariate model adjusting for age, gender, HCV-genotype, BMI, HOMA-IR, 
lipid profile and PNPAL3 genotype (adjusted estimate, -0.144; SE, 0.082; p=0.001). The 
distribution of rs58542926 genotype was not different according to HCV genotype.  
 As regards the metabolic profile, subjects with the TT genotype had significantly lower 
total cholesterol, LDL-C and TG, while paradoxically having significantly higher BMI and a 
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trend to higher HOMA-IR. The median of ALT, AST, GGT and ALP levels, and platelet counts 
were not significantly different between rs58542926 genotypes (Table 1). Similar results were 
observed when comparing CT/TT vs. CC (data not shown). For the purposes of comparison, the 
association of PNPLA3 rs738409 with the same variables was investigated. Apart from the fact 
that subjects with rs738409 GG genotype were significantly younger and had lower fasting 
blood glucose level, compared to subjects with CG and CC, no other significant associations 
were observed (Supplementary Table 3). 
Association between the TM6SF2 variant and histological features in the cohort with CHC 
 We next assessed in the CHC cohort, the association between TM6SF2 rs58542926 and 
histological features including steatosis, features of steatohepatitis (in 112 subjects), 
inflammation and fibrosis. The distribution of TM6SF2 rs58542926 genotypes according to 
histological features (steatosis grade, inflammation, and fibrosis) are depicted in Supplementary 
Figure 1. The rs58542926 T allele had a modest association with the degree of steatosis in a 
multivariate model adjusting for age, gender, HCV-genotype, BMI, HOMA-IR and PNPAL3 
genotype (adjusted estimate, 0.073; SE, 0.002; p=0.01) (Supplementary Table 4). When 
stratifying the cohort according to HCV genotype (genotype 3 vs. non-3) based on the direct 
effect of genotype 3 on steatosis (
33
), the rs58542926 was associated with steatosis only in non-
HCV-genotype 3 patients (adjusted estimate, 0.112, SE, 0.006; p=0.04). In contrast, PNPLA3 
rs738409 genotype was the strongest predictor of steatosis in both non-genotype 3 (adjusted 
estimate, 0.199, SE, 0.14; p=0.005) and in genotype 3 patients (adjusted estimate, 0.127, SE, 
0.077; p=0.03) (Supplementary Table 4).  
 We explored the association of rs58542926 with the severity of steatosis by subdividing 
the cohort according to absent/mild steatosis (S0-S1) compared to moderate/severe steatosis (S2-
12 
 
S3). In this analysis, rs58542926 was associated with the severity of steatosis (OR: 1.14, 95%CI: 
1.02-1.27, p=0.01), independent of PNPLA3 rs738409 (OR: 4.3, 95%CI: 1.94-9.52, p <0.0001) 
and other clinical variables (Table 2).  
 We then assessed the role of the TM6SF2 variant on hepatic inflammation. In 
multivariate analysis, neither TM6SF2 rs58542926, nor PNPLA3 rs738409 demonstrated any 
association with inflammation (Supplementary Table 5). No association was also observed 
when the cohort was dichotomized into absent/mild (A0-A1) and moderate/severe (A2-A3) 
inflammation. In sub-analysis of 112 subjects with genotype 1 CHC, we investigated the possible 
association between TM6SF2 rs58542926 and features of ‘steatohepatitis’ in CHC according to 
the Bedossa classification (
30
) and no association was observed (data not shown). Furthermore, 
no difference was noted in serum inflammatory markers (TNF-α, sTNFR2 and IL-6) or liver 
enzymes (ALT or AST; as indices of liver injury) according to rs58542926 genotype. 
Lastly, in the cross sectional analysis, we examined the impact of TM6SF2 rs58542926 genotype 
on fibrosis. The rs58542926 SNP was marginally associated with fibrosis stage in univariate 
analysis, but not in multivariate linear regression analysis controlling for age, gender, steatosis, 
HOMA-IR, BMI, HCV genotype, alcohol intake and PNPLA3 genotype (adjusted estimate, 
0.071, SE, 0.003; p=0.06) (Supplementary Table 5). The adjusted OR for having significant 
fibrosis (≥F2) was 1.39 (95% CI: 1.04-1.87, p=0.02) for the T allele, and with cirrhosis (>F4) 
was 1.82 (95% CI: 1.01-3.28, p=0.04) (Table 2). 
Association between the TM6SF2 variant and fibrosis progression 
 Given the inherent biases in cross sectional analyses, the lack of impact of TM6SF2 
rs58542926 genotype on hepatic inflammation, the principal driver of liver fibrosis, and the 
modest impact on fibrosis stage (absent in multivariate linear regression and present by 
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multivariate logistic regression), we undertook further analysis in 1,174 patients with CHC and a 
known duration of infection, allowing us to assess the relationship with fibrosis progression. The 
baseline characteristics of the cohort were similar among subjects included and not included in 
the fibrosis progression sub-analysis (Supplementary Table 6). The OR of rs58542926 for 
having fast FPR was 1.31 (95% CI: 1.08-2.97, p=0.03), while after adjustment, the T allele was 
not independently associated with FPR (p= 0.5) (Supplementary Table 7).  
 For further confirmation, we assessed fibrosis progression using Cox-proportional 
hazards to address the concern that FPR may not be constant over time (
34
). rs58542926 was not 
associated with an increased hazard of progression to significant fibrosis (≥ F2) in univariate or 
multivariate models (hazards ratio: 1.43, 95% CI: 0.64-3.21, p=0.3), including when adopting 
other genetic models. In contrast, rs738409 in PNPLA3 showed a trend for significance (hazards 
ratio: 1.34, 95% CI: 0.97-1.84, p=0.06), but again not in a multivariate model (Figure 1). In 
another model, rs58542926 was not associated with an increased hazard of progression to 
cirrhosis (F4) (hazards ratio: 1.16, 95% CI: 0.16-8.39, p=0.8), supplementary figure 2. 
 There was no evidence of interaction between rs58542926 and rs738409 on any 
histological features (steatosis, inflammation and fibrosis) (data not shown). 
 In sum, the TM6SF2 rs58542926 T allele was associated with a modest risk of hepatic 
steatosis in CHC, being more profound in subjects with non-genotype 3 infection. There was no 
effect of the T allele on inflammation, while an effect on fibrosis stage was at best, modest, with 
no effect on fibrosis progression. The effect of the TM6SF2 rs58542926 T allele was 
independent of PNPLA3 738409.  
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Relationships between rs58542926 genotype and hepatic gene expression  
 There was a significant relationship between carriage of the rs58542926 T allele and 
lower TM6SF2 mRNA expression (p=0.001, Figure 2 B). Expression of SREBP1c, FAS and 
ACOX1 mRNA, as markers of lipid synthesis and oxidation, were not significantly different 
according to rs58542926 genotype. As expected however, serum TG was significantly lower in 
subjects with the rs58542926 CT/TT than CC genotype (Figure 2 C). The expression of MTTP, 
a key protein involved in TG packaging and export was significantly lower in liver from subjects 
with the T allele (Figure 2C). These results suggest that in CHC, carriers of the T allele for 
rs58542926 have reduced TM6SF2 and MTTP expression, concomitant with reduced serum TG 
levels.  
Other chronic liver diseases 
Chronic hepatitis B 
 The characteristics of 507 Chinese patients with CHB are summarized in Supplementary 
Table 8. The TM6SF2 rs58542926 MAF of 0.07 was similar to that observed in Caucasian 
populations, and in other Han Chinese population cohorts (
13
) (Supplementary Table 1). The 
distribution of TM6SF2 rs58542926 genotypes according to histological features (steatosis 
grade, inflammation, and fibrosis) are depicted in Supplementary Figure 3. The rs58542926 T 
allele was associated with steatosis (adjusted estimate, 0.094; SE, 0.003; p=0.03), but, in 
particular, with presence of any steatosis (S0 versus S ≥1) (OR=2.57, 95%CI: 1.36-4.86, 
P = 0.003) rather than with severe steatosis (S0-S1 versus S2-S3) (OR=1.49, 95%CI: 0.83-2.67, 
P = 0.1) (Table 3). No association was observed between rs58542926 genotype and 
inflammation or fibrosis (Supplementary Table 9). Notably, only classic risk factors such as 
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age and gender demonstrated an independent association with fibrosis (Supplementary Table 
10), and PNPLA3 rs738409 showed no association with either inflammation or fibrosis.  
 Again, as noted in other liver diseases cohorts, subjects with the T allele had lower serum 
TG and LDL-C, but this was significant only for the latter (p=0.008). Interestingly, in contrast to 
what was observed in CHC, patients with CHB had higher HBV-DNA levels (p=0.04) 
(Supplementary Table 11). The association with HBV-DNA levels remained significant after 
adjusting for age, gender, BMI, presence of diabetes, lipid profile and PNPAL3 genotype 
(adjusted estimate, 0.103; SE, 0.036; p=0.03). For PNPLA3 rs738409, apart from higher serum 
HDL-C in subjects with the GG genotype, no other significant associations were demonstrated 
(Supplementary Table 12).  
NAFLD 
 The characteristics of 502 Caucasian patients with NAFLD are summarized in 
Supplementary Table 13. The MAF for rs58542926 in the NAFLD cohort was 0.12 with an 
increase in T allele frequency compared to healthy controls (X
2
 for trend, P=0.01; 
Supplementary Table 1). The distribution of TM6SF2 rs58542926 genotypes according to 
histological features (steatosis grade, inflammation, and fibrosis) are depicted in Supplementary 
Figure 4. rs58542926 was associated with the risk of fatty liver (adjusted estimate, 0.111; SE, 
0.097; p=0.02); this was independent of age, gender, BMI, presence of diabetes, hypertension, 
and PNPLA3 rs738409 genotype (Supplementary Table 14).  
 rs58542926 demonstrated an independent association with stage of fibrosis (adjusted 
estimate, 0.189; SE, 0.117; p=0.003) and with risk of significant fibrosis (≥ F2) in multiple 
logistic regression analysis (OR:1.62, 95% CI: 1.03.-2.52, p=0.03) (Table 4). Nevertheless, 
analysis of the relationship between rs58542926 and steatohepatitis did not demonstrate a 
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significant association (p=0.6) (Supplementary Table 14). Likewise, we observed a lack of 
association between the gene variant and the NAS score (data not shown). There was no 
interaction between PNPLA3 rs738409 and TM6SF2 rs58542926 variants on any histological 
features (steatosis, steatohepatitis or fibrosis) in NAFLD.  
 As expected, subjects with the rs58542926 TT genotype had lower serum TG and ALP 
levels, while no association was demonstrated with either serum ALT or AST values or with 
other metabolic parameters (Supplementary Table 15). As a control, the rs738409 PNPLA3 GG 
genotype demonstrated significantly higher ALT, AST and GGT (Supplementary Table 16), 
consistent with its independent association with steatohepatitis (adjusted estimate, 0.103; SE, 
0.048; p=0.03), but no association was observed with the serum lipid profile. In a joint analysis 
of all cohorts (HCV, HBV, NAFLD), rs58542926 genotype showed no association with ALT, 
AST or GGT.  
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Discussion 
 We clarified the influence of the TM6SF2 rs58542926 variant on the metabolic and 
histological features of viral hepatitis as compared to that in NAFLD. The most noteworthy 
finding was that the E167K substitution had a consistent effect on the serum metabolic profile 
and the predisposition to hepatic steatosis, rather than to hepatic inflammation and fibrosis across 
all three diseases. This effect was independent and not additive to the influence of the PNPLA3 
rs738409 C/G (I148M) polymorphism. Consistent with a crucial role for lipids in hepatitis virus 
replication, a novel observation was that the TM6SF2 T allele has significant and opposite 
associations with HCV-RNA and HBV-DNA levels. Mechanistically, we show in a subset of 
patients, that alteration in MTTP expression in the liver of carriers with the T allele, might 
contribute to the hepatic and serum metabolic abnormalities observed. 
 Across all analyses and disease cohorts, the TM6SF2 T allele conferred a modest risk for 
hepatic steatosis with estimates varying from (0.111, 0.073 and 0.094) in NAFLD, CHC and 
CHB, respectively, which is less than the risk for PNPLA3 rs738409 (0.168, 0.159 and 0.119 
respectively), and for established risk factors such as T2DM, BMI and HCV genotype 3. 
Likewise, carriage of the T allele was associated with lower serum lipoproteins in NAFLD, and 
as we demonstrate for the first time, in chronic viral hepatitis. To gain insights on the function of 
TM6SF2 in patients with liver disease, we investigated the correlation of rs58542926 genotype 
with hepatic expression of TM6SF2. The rs58542926 T allele was associated with lower hepatic 
TM6SF2 gene expression, a finding consistent with that observed by gene expression and eQTL 
analysis of incidental liver biopsies from 206 patients undergoing aortic valve surgery (
18
). In 
that study, patients were segregated according to rs10401969 rather than the rs58542926 
genotype. However, rs10401969 is in strong linkage disequilibrium (LD) with the non 
synonymous variant rs58542926 (r2 > 0.99) identified by the genome-wide exome association 
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study (
18
). This is also consistent with another recent study demonstrating that the rs58542926 T 
allele is associated with decreased gene and protein expression in liver of NAFLD patients (
12
). 
 Of interest, in the CHC sub-cohort, we show that MTTP expression, required for VLDL 
assembly and maturation was reduced with carriage of the T allele, while the expression of genes 
involved in lipid synthesis and oxidation (SREBP1c, FAS and Acox1 mRNA) were unaffected.  
 This human data is consistent with, and adds to recent observations from Tm6sf2 
overexpression and knockdown in mice and in vitro studies demonstrating that TM6SF2 is a key 
modulator of TG-rich lipoproteins and apolipoprotein B (apoB)  (
9,18
). In humans, TG is 
delivered to adipose tissues by intestinally-derived chylomicrons and by hepatic VLDL synthesis 
(
35
). Notably, both liver and intestine express the highest levels of TM6SF2 (
9,18
). MTTP is 
absolutely required for VLDL assembly and maturation (
36
), catalyzing the transport of 
triglyceride, cholesteryl ester and phospholipids to the nascent apoB molecule, that is required 
for the assembly and secretion of VLDL and low-density lipoproteins (LDLs) (
37
). MTTP is 
found in abundance on the luminal side of the ER and in the liver, intestine, and heart (
38
), and 
thus it is of interest that a recent study using confocal microscopy observed localization of green 
fluorescent protein–tagged TM6SF2 to the ER of 2 human hepatoma cell lines (Huh7 and 
HepG2) (
18
). In that study, knockdown of TM6SF2 in both cell lines had no effect on the 
expression of APOB or MTTP, however whether MTTP expression is altered based on TM6SF2 
genotype was not tested.  
 Of particular interest is the significant and opposite association between the TM6SF2 
variant and HCV and HBV viral load, with the T allele associated with lower HCV-RNA levels 
but higher HBV-DNA. The association remained significant (p=0.001 with CHC and p=0.03 
with CHB) after controlling for the main confounders. Although our analyses do not allow for a 
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mechanistic explanation, it is consistent with previous reports from population based studies and 
experimental models indicating that HCV-RNA levels correlate positively, while HBV-DNA 
levels correlate inversely with serum TG (
21-23
). From a teleological standpoint, the question 
remains how the E167K substitution in TM6SF2 rs58542926 might favor HBV replication and 
inhibit HCV. Previous studies have shown that blocking VLDL secretion by inhibiting MTTP 
with naringenin reduces the export of HCV (
39
), while overexpression of seipin, a protein 
implicated in the maturation and fusion of lipid droplets (LDs) in hepatoma cells subsequently 
infected with HCV causes a significant decrease in virion export, accompanied by the 
appearance of large LDs (experimental steatosis) (
40
). Thus, our data if confirmed suggests that 
the functional consequence of the E167K substitution in TM6SF2 by blocking VLDL export 
might also restrict HCV export and hence viral load.  
 Although the interaction of the HBV life cycle with lipid metabolism is not well 
characterized, it has been suggested that lipids play a vital role in HBV replication (
41
). While 
acute hepatitis B is associated with transient hypertriglyceridemia (
42
), CHB is associated with 
reduced serum TG and total cholesterol (
43
). Several studies suggest that the HBV X protein 
(HBx) induces lipid accumulation in HepG2–HBx stable cells and in HBx-transgenic mice (44,45) 
by activation of lipogenic and fatty acid synthesis genes such as SREBP1 and peroxisome 
proliferator-activated receptor γ (PPARγ), and inhibiting the secretion of apoB. Likewise, in 
HepG2–HBV-stable cells, virus replication upregulates adipogenic gene expression 
(CCAAT/enhancer binding protein α (C/EBPα), PPARγ, adiponectin, liver X receptor α (LXRα), 
SREBP1c, and Fas). Further, adiponectin and the PPARγ agonist rosiglitazone stimulate viral 
replication (
46
). Thus, promotion of lipid synthesis, and blockage of lipid secretion are important 
pathways in HBV infection suggesting that hepatic steatosis induced by the E167K substitution 
could promote HBV replication. However, this hypothesis needs further investigation.   
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 A recent study has suggested that the prevalence of the rs58542926 T allele is reduced in 
European Caucasians with CHC (
15
), a finding we have been unable to replicate in the total 
cohort with CHC or in the different European and Australian centers, or in a the cohort of Asians 
with chronic hepatitis B. The reason for this discrepancy is not clear. Of relevance, whether 
rs58542926 is involved in HCV or HBV spontaneous clearance requires further investigation. 
The TM6SF2 rs58542926 MAF of 0.07 in our Chinese patients with CHB was similar to that 
observed in Caucasian populations, and in other Han Chinese population cohorts (
13
). 
 In our three cohorts, we were able to undertake robust analysis to assess the role of the 
E167K substitution on the more controversial aspects of liver histology, namely inflammation 
and fibrosis. The TM6SF2 rs58542926 variant had no detectable effect on inflammation in all 
three chronic liver diseases, whether by histological grade, liver enzymes (ALT or AST) or in a 
subset with CHC, the levels of serum inflammatory markers (TNF-α, IL-6 and sTNFR2). Thus, 
clearly, if the E167K substitution in TM6SF2 rs58542926 contributes to liver fibrosis, as has 
been suggested (
10,15
) it is likely mediated by a process other than hepatic necroinflammation.  
 To confirm or refute a role for the E167K substitution in TM6SF2 on liver fibrosis, the 
cohort of nearly 1200 patients with CHC and a known duration of infection had us uniquely 
positioned to assess fibrosis progression, compared to all previous reports. In this analysis, 
rs58542926 genotype had no effect on fibrosis progression assessed using either stage-constant 
fibrosis progression rates or Cox regression to model the time taken for significant fibrosis (≥ 
F2) or cirrhosis (≥ F4) to develop. Likewise, in cross sectional analyses of the total cohort with 
CHC (n=2023), the rs58542926 T allele was not associated with fibrosis stage in adjusted 
multivariate linear regression analysis, while it only showed an association with ≥F2 fibrosis 
(OR: 1.39) and with cirrhosis (OR: 1.82) by logistic regression, consistent with a recent report 
(
15
). In CHB, likewise, we demonstrated no significant association of the rs58542926 variant 
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with fibrosis stage, significant fibrosis (F2-F4), severe fibrosis (F3-F4) or with cirrhosis. In cross 
sectional analysis of the NAFLD cohort, as with previous reports (
10,11
), we confirmed an 
association of the rs58542926 variant with more severe fibrosis stage and with significant 
fibrosis. The adjusted estimate and OR for rs58542926 (β=0.136 and OR=1.62, respectively) 
was lower than these values for either PNPLA3 rs738409 (β=0.1819 and OR=1.98, respectively) 
or classic clinical risk variables such as age, diabetes and hypertension. 
 Thus, in sum, our analyses indicates that the E167K substitution in TM6SF2 rs58542926 
has marginal if any effect on fibrosis in chronic viral hepatitis, and no effect on inflammation or 
fibrosis progression. In NAFLD, perhaps because steatosis occurs in the context of systemic 
metabolic dysregulation and oxidant stress from intra-hepatic toxic lipid species such as 
unesterified free fatty acids and ceramides (
47
), the TM6SF2 rs58542926 variant more 
consistently amplifies and contributes to fibrosis. It should be noted, that the present analysis is 
unable to dissect whether the effect of the TM6SF2 variant on fibrosis is direct or indirect 
through its association with metabolic derangements. 
 Unfortunately, data on viral clearance was not available in order to investigate the clinical 
relevance of our observations regarding TM6SF2 rs58542926 with HCV and HBV viral load. 
Further, it should be acknowledged that population stratification was not assessed in detail. 
However, all participants with CHC and NAFLD were of Caucasian ancestry and all CHB 
patients were Chinese. It should be noted that population structure is more critical when studying 
rare variants (
48
), while rs58542926 does not fit into this category (MAF=0.07), and we did not 
observe any difference in MAF between the different centres.  
 In conclusion, this is the first study to compare the diverse impacts of the rs58542926 
E167K variant in TM6SF2 on the metabolic and histological features of metabolic and viral liver 
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disease. We demonstrate that the E167K substitution in TM6SF2 is associated with altered serum 
lipoproteins and susceptibility to hepatic steatosis in viral and non viral chronic liver disease, and 
with reduced hepatic MTTP expression in the HCV cohort. Though, the TM6SF2 rs58542926 
minor allele influenced fibrosis in NAFLD, it had no discernable effects on liver inflammation, 
and perhaps only a minor influence on hepatic fibrosis, in chronic viral hepatitis. Importantly, the 
variant is associated with viral load, in opposing directions in CHC as compared to CHB, likely 
modulated by the differential effects of hepatic lipid metabolism and export, on the HBV and 
HCV virus life cycle.  
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Figures legends: 
Figure 1: Univariate Cox regression analysis of TM6SF2 rs58542926 and PNPLA3 rs738409 genotype 
on the cumulative probability of progression to moderate/severe (≥F2) fibrosis in 1174 patients with a 
known duration of HCV infection. Similar results was observed in multivariate Cox regression analysis 
after adjusting for covariates (age, gender, BMI, duration of the infection, HCV genotype, inflammation 
progression, and basal ALT, AST, GGT, platelets, bilirubin and alkaline phosphatase). Data of TM6SF2 
rs58542926 and PNPLA3 rs738409 genotype are shown in dominant and additive models, respectively. 
No difference was observed in other genetic models.  
 
Figure 2: A) Relationship between rs58542926 genotype and serum triglyceride level in 1059 patients 
with CHC. In human liver samples from patients with CHC: B) Relationship between rs58542926 
genotype and TM6SF2 mRNA levels C) Relationship between rs58542926 genotype and the expression 
of sterol regulatory element binding protein-1c (SREBP-1c), fatty acid synthase (FAS), acyl-coenzyme A 
oxidase 1 (ACOX1) and microsomal triglyceride transfer protein (MTTP).  
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